ACTION FOR A-T — grant history
Latest income
£905k
Grants listed (FY2025)
13
Listed grants total
£1.7m
Accounts grants total
£116k
listed grants do not fully reconcile with the accounts total — list may be partialextracted from its FY2025 accounts
What changed: FY2024 → FY2025
| Change | Grantee | FY2024 | FY2025 |
|---|---|---|---|
| new | Universities of Birmingham, UK & Hamburg, Germany | — | £250k |
| new | University of North Carolina, USA | — | £249k |
| new | QIMR Berghofer Medical Research Institute, Queensland, Australia | — | £58k |
| new | University of Cambridge, UK | — | £20k |
| not listed | University of Hamburg and University of Birmingham | £250k | — |
| not listed | University of North Carolina at Chapel Hill, USA | £249k | — |
| not listed | University College London (UCL), UK | £25k | — |
| not listed | University of Nottingham | £20k | — |
| not listed | University of Cambridge | £20k | — |
Grants made, per its accounts filings
| Recipient | Year | Amount | Purpose |
|---|---|---|---|
| Leiden University Medical Centre, Netherlands | FY2025 | £250k | Functional impact of Nicotinamide Riboside on the immune system of patients with A-T |
| University of Kent, UK | FY2025 | £250k | Investigating the role of mutant triple T chaperone in ATM assembly in A-T |
| Universities of Birmingham, UK & Hamburg, Germany | FY2025 | £250k | Development of suppressor tRNA-based therapeutics |
| University of Birmingham, UK | FY2025 | £249k | Identifying existing drugs to repurpose for treating A-T |
| University of North Carolina, USA | FY2025 | £249k | Development of a gene therapy approach to treat A-T |
| University of Nottingham, UK | FY2025 | £247k | Biomarkers for babies and young children with A-T |
| QIMR Berghofer Medical Research Institute, Queensland, Australia | FY2025 | £58k | Dose response and mechanistic profiling of two candidate neuroactive drugs in A-T cerebellar organoids |
| University of Nottingham, UK | FY2025 | £20k | Exploring the use of assistive robots, smart sensing & digital twin models for monitoring and support of Ataxia in non-clinical environments |
| University of Cambridge, UK | FY2025 | £20k | Improving diagnosis and treatment of cancer in A-T patients through whole genome sequencing |
| University of Nottingham, UK | FY2025 | £20k | Developing a Safer Immune‑Based Treatment for Blood Cancers in Children and Adults with A‑T |
| University of Nottingham, UK | FY2025 | £20k | A prospective pilot study to compare lung CT and MRI in Ataxia Telangiectasia |
| University of Nottingham, UK | FY2025 | £19k | Kicking Kinases into action: A novel drug screening assay for A-T |
| University of Nottingham, UK | FY2025 | £18k | Improving future treatments for Ataxia-Telangiectasia through better delivery of RNA-based therapies |
| Leiden University Medical Centre, Netherlands | FY2024 | £250k | Functional impact of Nicotinamide Riboside on the immune system of patients with A-T |
| University of Kent, UK | FY2024 | £250k | Investigating the role of mutant Triple T chaperone in ATM assembly in Ataxia Telangiectasia |
| University of Hamburg and University of Birmingham | FY2024 | £250k | Development of suppressor tRNA-based therapeutics |
| University of Birmingham, UK | FY2024 | £249k | Identifying existing drugs to repurpose for treating Ataxia-Telangiectasia |
| University of North Carolina at Chapel Hill, USA | FY2024 | £249k | Development of a Gene Therapy approach to treat A-T |
| University of Nottingham, UK | FY2024 | £247k | Biomarkers for Babies and Young Children with Ataxia Telangiectasia (BOBCAT) |
| University College London (UCL), UK | FY2024 | £25k | Exploring Omaveloxolone efficacy in Ataxia-telangiectasia |
| University of Nottingham | FY2024 | £20k | Exploring the Use of Assistive Robots, Smart Sensing and Digital Twin Models for Monitoring and Support of Ataxia in Non-Clinical Environments |
| University of Cambridge | FY2024 | £20k | Improving diagnosis and treatment of cancer in Ataxia-Telangiectasia patients through whole genome sequencing |
| University of Nottingham | FY2024 | £19k | Kicking Kinases into Action: A novel drug screening assay for A-T |
| Oslo University Hospital, Norway | FY2023 | £25k | Preclinical Assessment of Intrathecal rAAV9-Mediated miATM Therapy for Ataxia Telangiectasia in Mouse Models |
| Institute for Bioengineering of Catalonia, Spain | FY2023 | £25k | Modelling Ataxia Telangiectasia pathogenesis and therapeutics using human pluripotent stem cells and genetic engineering |
| University of Nottingham, UK | FY2023 | £20k | STIM A-T Pilot Study |
| University of Nottingham, UK | FY2023 | £19k | Virtual Reality in Ataxia-Telangiectasia |
| University of Nottingham, UK | FY2023 | £863 | Sandpit Event |
| University of Cambridge, UK | FY2022 | £250k | Trial REadiness in Ataxia Telangiectasia (TREAT-AT) |
| QIMR Berghofer Medical Research Institute, Queensland, Australia | FY2022 | £152k | Digital drug prediction informed by genetic analysis of stem cell-derived mini-brains from A-T patients |
| University of Nottingham, UK | FY2022 | £147k | Brain-penetrating ATM gene therapy |
| IFOM – The FIRC Institute of Molecular Oncology, Milan, Italy | FY2022 | £126k | Understanding and correcting glucose metabolism defects in Ataxia-Telangiectasia |
| Bambino Gesù Children’s Hospital, Italy | FY2022 | £91k | Study of natural killer cells in A-T pathogenesis and their therapeutic implications |
| Duke University, USA | FY2021 | £250k | A new function for ATM and a new theory for the clinical abnormalities in A-T |
| University of Rochester, USA | FY2021 | £247k | Recurrent pulmonary infections and their impact on neurological decline in A-T |
| University of Texas, USA | FY2021 | £23k | A-T cerebellar neurodegeneration and inositol phosphate signalling |
Write-backs & cancellations
| Recipient | Year | Amount | Purpose |
|---|---|---|---|
| Nottingham University Hospital, UK | FY2023 | −£22k | Natural History of A-T (underspends refunded) |
| University of Birmingham, UK | FY2023 | −£15k | Assessment of the frequencies and types of cancers occurring in A-T patients (underspends refunded) |
| University of Birmingham, UK | FY2023 | −£29 | Deciphering the molecular mechanism linking Ataxia-Telangiectasia and Ataxia-Telangiectasia-Like Disorder (underspends refunded) |
| Nottingham University Hospital, UK | FY2022 | −£22k | (Research project underspends refunded) Natural History of A-T |
| University of Birmingham, UK | FY2021 | −£33k | (Research project underspends refunded) Identifying new therapies for blood cancers in patients with A-T |
| Oxford University, UK | FY2021 | −£16k | (Research project underspends refunded) - The use of patient stem cell-derived mini-brains to study A-T |
| Imagin Institute Paris, France | FY2021 | −£7k | (Research project underspends refunded) - Does irregular repair of DNA damage in Neurons and Lymphocytes cause cellular degeneration in A-T patients? |
| Nottingham University Hospital, UK | FY2021 | −£7k | (Research project underspends refunded) longitudinal brain changes in childhood A-T |